Sign In
Buy DLHC
DLH Holdings Earnings Calls
| Release date | Dec 03, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Expected change | +/- 4.76% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Revenue estimate | 83.5M |
| Revenue actual | 83.343M |
| Revenue Surprise | -0.188% |
| Release date | May 07, 2025 |
| EPS estimate | $0.0700 |
| EPS actual | $0.0600 |
| EPS Surprise | -14.29% |
| Revenue estimate | 90M |
| Revenue actual | 89.212M |
| Revenue Surprise | -0.88% |
| Release date | Feb 05, 2025 |
| EPS estimate | $0.0700 |
| EPS actual | $0.0800 |
| EPS Surprise | 14.29% |
| Revenue estimate | 97M |
| Revenue actual | 90.782M |
| Revenue Surprise | -6.41% |
Last 4 Quarters for DLH Holdings
Below you can see how DLHC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 05, 2025 |
| Price on release | $7.22 |
| EPS estimate | $0.0700 |
| EPS actual | $0.0800 |
| EPS surprise | 14.29% |
| Date | Price |
|---|---|
| Jan 30, 2025 | $7.60 |
| Jan 31, 2025 | $7.50 |
| Feb 03, 2025 | $7.39 |
| Feb 04, 2025 | $7.37 |
| Feb 05, 2025 | $7.22 |
| Feb 06, 2025 | $6.33 |
| Feb 07, 2025 | $6.35 |
| Feb 10, 2025 | $6.24 |
| Feb 11, 2025 | $6.03 |
| 4 days before | -5.00% |
| 4 days after | -16.48% |
| On release day | -12.33% |
| Change in period | -20.66% |
| Release date | May 07, 2025 |
| Price on release | $4.05 |
| EPS estimate | $0.0700 |
| EPS actual | $0.0600 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| May 01, 2025 | $3.93 |
| May 02, 2025 | $3.92 |
| May 05, 2025 | $3.97 |
| May 06, 2025 | $4.06 |
| May 07, 2025 | $4.05 |
| May 08, 2025 | $4.08 |
| May 09, 2025 | $4.15 |
| May 12, 2025 | $4.60 |
| May 13, 2025 | $4.83 |
| 4 days before | 3.05% |
| 4 days after | 19.26% |
| On release day | 0.741% |
| Change in period | 22.90% |
| Release date | Aug 06, 2025 |
| Price on release | $5.56 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Date | Price |
|---|---|
| Jul 31, 2025 | $5.61 |
| Aug 01, 2025 | $5.52 |
| Aug 04, 2025 | $5.59 |
| Aug 05, 2025 | $5.50 |
| Aug 06, 2025 | $5.56 |
| Aug 07, 2025 | $5.55 |
| Aug 08, 2025 | $5.50 |
| Aug 11, 2025 | $5.46 |
| Aug 12, 2025 | $5.55 |
| 4 days before | -0.89% |
| 4 days after | -0.180% |
| On release day | -0.180% |
| Change in period | -1.07% |
| Release date | Dec 03, 2025 |
| Price on release | - |
| EPS estimate | $0.0200 |
| EPS actual | - |
| Date | Price |
|---|---|
| Nov 11, 2025 | $5.86 |
| Nov 12, 2025 | $5.87 |
| Nov 13, 2025 | $5.85 |
| Nov 14, 2025 | $5.98 |
| Nov 17, 2025 | $5.80 |
DLH Holdings Earnings Call Transcript Summary of Q2 2025
Key investor takeaways: DLH reported Q2 fiscal 2025 revenue of $89.2M (vs. $101M LY) and adjusted EBITDA of $9.4M (10.5% margin vs. 10.1% LY). Revenue was pressured (~$11.8M) by conversion of certain VA and DoD programs (CMOP) to small-business set‑asides, though DLH has short-term extensions on several CMOP sites through October 2025 which should contribute an estimated $23–$25M quarterly run rate for the remaining locations. Operating cash generation improved materially (≈$14.5M in Q2), and management used cash to reduce debt by $15.3M during the quarter (ending period debt $151.7M), putting the company comfortably ahead of debt covenants (~80 bps). Management highlighted a robust new‑business pipeline — describing both >$1B of contracts under active review and an estimated $3.5B of qualified opportunities (more than 4x revenue) — with expected award activity in the second half of the fiscal year. Recent wins include advanced technology and R&D work for the U.S. Army Medical Research & Development Command and continued progression of a large Navy contract. Principal near‑term risks are procurement delays, program set‑asides/unbundling under the new administration and changes to contract administration that can slow awards and invoice approval; management believes overall administration impacts are neutral-to-slightly-positive for DLH and is focused on deleveraging and winning higher‑margin, technology‑enabled work.
